News Breaks |
|
|
| June 25, 2012 |
| 10:16 EDT |  | NVS, TEVA, MYL, MNTA | Teva rises, Momenta falls following Copaxone patent ruling
Sharesof Teva (TEVA) advanced following a favorable ruling for the company in a patent infringement lawsuit against Momenta Pharmaceuticals (MNTA), Mylan (MYL) and Sandoz, a unit of Novartis (NVS). Wells Fargo called the ruling related to Teva's Copaxone, a drug for the treatment of relapsing-remitting multiple sclerosis, a major victory that provides a path for sustainable long-term growth for the company. RBC Capital raised its price target on Teva shares to $52 from $48, saying the ruling should block generic competition for the drug until the 2014 Orange Book listed patents expire. Meanwhile, Momenta said that it was disappointed by the court's determination and intends to appeal. Canaccord downgraded Momenta shares to a Hold rating from Buy after the decision, cutting its price target on shares to $12 from $17. In early morning trading, Teva shares rose $2.33, or 6.13%, to $40.34. Shares of Momenta Pharmaceuticals plunged $3.03, or 17.79%, to $13.98 while Mylan fell 23c, or 1.08%, to $21.00 and Novartis slid 78c, or 1.42%, to $54.10. |
|
|
News For TEVA;MNTA;MYL;NVS From The Last 14 Days Check below for free stories on TEVA;MNTA;MYL;NVS the last two weeks. |
|
|
| May 21, 2013 |
| 07:44 EDT |  | NVS | Sachs Associates to host a forum
 Subscribe for More Information |
|
| 07:35 EDT | | MYL | Mylan: Appellate Court rules in favor of company in patent infringement case
Subscribe for More Information |
|
| 07:24 EDT | | NVS | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 11:27 EDT | | TEVA, MYL | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| 07:29 EDT | | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| May 17, 2013 |
| 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
Subscribe for More Information |
|
| 14:48 EDT |  | MYL | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information |
|
| 13:56 EDT | | MYL | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. |
|
| 07:31 EDT | | MYL | Mylan launches generic Tricor tablets
Subscribe for More Information |
|
| May 16, 2013 |
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
| |
| May 15, 2013 |
| 19:37 EDT | | NVS, MYL | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
| 17:36 EDT | | MYL | Paulson gives quarterly update on stakes
Subscribe for More Information |
|
| 11:42 EDT | | MYL | Mylan launches generic Zomig tablets
Subscribe for More Information |
|
| 07:03 EDT |  | MYL | Mylan highly unlikely to acquire Actavis, says Barclays
Subscribe for More Information |
|
| May 14, 2013 |
| 13:55 EDT | | MYL | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information |
|
| 13:22 EDT | | MYL | Actavis turned down $15B takeover bid from Mylan, Bloomberg reports
Subscribe for More Information |
|
| May 13, 2013 |
| 09:44 EDT | | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:49 EDT | | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. |
|
| May 10, 2013 |
| 10:00 EDT |  | MYL, TEVA | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
| |
|
|
|
|
